Baricitinib: The Immunomodulator of Choice for Severe COVID-19—The Verdict Is In

Andre C. Kalil, Carlos A. Gomez

Research output: Contribution to journalEditorialpeer-review

Original languageEnglish (US)
Pages (from-to)e186-e189
JournalCritical care medicine
Volume53
Issue number1
DOIs
StatePublished - Jan 1 2025

Keywords

  • baricitinib
  • COVID-19
  • dexamethasone
  • tocilizumab

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Cite this